50 completed, 33 unknown, 20 recruiting, 10 terminated. 37 Phase 2, 35 Phase 4, 23 Not applicable, 23 Phase 3, 9 Phase 1.
Follow Glucocorticoids: new trials by email Literature Review of Glucocorticoids trials Research Report on Glucocorticoids
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy | Phase 4 | Recruiting | Sarepta Therapeutics, Inc. | 20 | 2026-11-30 | 2026-11-12 |
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-11-09 |
| Autologous Circulating Extracellular Vesicles for Total-Type Sudden Sensorineural Hearing Loss autologous circulating extracellular vesicles, Glucocorticoids - Sudden Sensorineural Hearing Loss (SSNHL) | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 146 | 2026-09-15 | 2026-10-16 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Momelotinib, Glucocorticoids, Placebo - VEXAS Syndrome | Phase 2 / Phase 3 | Not yet recruiting | GlaxoSmithKline | 136 | 2026-08-05 | 2026-06-01 |
| 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study IV glucocorticoid and antihistamine, IV glucocorticoid and antihistamine (standard of care) - Allergic Reaction to Contrast Media, Hypersensitivity Reaction | Not applicable | Not yet recruiting | Paul Peng, MD PhD MSCR | 540 | 2026-06-01 | 2026-02-19 |
| Bosentan in the Treatment of Giant Cell Arteritis Bosentan, Glucocorticoids - Giant Cell Arteritis (GCA) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 40 | 2026-06-01 | 2026-05-06 |
| Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares Glucocorticoid (GC) - Rheumatoid Arthritis (RA) | Phase 4 | Recruiting | Sunnybrook Health Sciences Centre | 220 | 2026-04-01 | 2026-04-13 |
| A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia Glucocorticoids - Autoimmune Hemolytic Anemia (AIHA) | Not applicable | Not yet recruiting | Chen Miao | 216 | 2026-04-01 | 2026-04-08 |
| The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment Glucocorticoids, belimumab, Telitacicept - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | Nanjing University School of Medicine | 50 | 2025-12-08 | 2026-03-12 |
| RCT of Tocilizumab for Anti-MDA5+DM Tocilizumab, Standard medical treatment - Dermatomyositis | Not applicable | Recruiting | Peking Union Medical College Hospital | 110 | 2025-11-01 | 2026-01-29 |
| A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1 / Phase 2 | Not yet recruiting | Chao Ji | 100 | 2025-10-01 | 2024-10-29 |
| A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease Rilzabrutinib, Placebo, Glucocorticoid - Immunoglobulin G4 Related Disease | Phase 3 | Recruiting | Sanofi | 124 | 2025-09-26 | 2026-10-20 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 96 | 2025-04-15 | 2025-09-03 |
| The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment. IBI311, Glucocorticoids - Thyroid Associated Ophthalmopathies | Phase 4 | Recruiting | Shanghai Changzheng Hospital | 64 | 2025-04-10 | 2025-09-03 |
| A Single-center Study of CM313 in Patients With Pemphigus CM313 injection, glucocorticoids - Pemphigus | Not applicable | Not yet recruiting | Sichuan Provincial People's Hospital | 20 | 2025-04-01 | 2025-04-01 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease Glucocorticoid Effect - Osteoporosis, Osteoporosis, Steroid Induced | Recruiting | Diakonhjemmet Hospital | 160 | 2025-01-01 | 2026-08-19 | |
| Efficacy and Safety of Telitacicept in IgAN Telitacicept 240mg, Glucocorticoid - IgA Nephropathy (IgAN), Kidney Diseases | Not applicable | Recruiting | Ruijin Hospital | 118 | 2024-12-06 | 2025-01-01 |
Showing 20 of 128. Sign in to see all of them.
Arthritis, Rheumatoid (10) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (9) · Granulomatosis with Polyangiitis (8) · Glomerulonephritis, Membranous (5) · Microscopic Polyangiitis (5) · Recurrence (5) · Vasculitis (5) · Aspergillosis, Allergic Bronchopulmonary (4) · Giant Cell Arteritis (4) · Graves Ophthalmopathy (4) · Immunoglobulin G4-Related Disease (3) · Lung Diseases, Interstitial (3) · Lupus Erythematosus, Systemic (3) · Lupus Nephritis (3) · Prostatic Neoplasms (3)
Peking Union Medical College Hospital (5) · Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · Beijing Tongren Hospital (2) · Chinese SLE Treatment And Research Group (2) · Huashan Hospital (2) · Insel Gruppe AG, University Hospital Bern (2) · Janssen Research & Development, LLC (2) · Jawaharlal Institute of Postgraduate Medical Education & Research (2) · Massachusetts General Hospital (2) · Medical University of South Carolina (2) · Medical University of Vienna (2) · Nanfang Hospital, Southern Medical University (2) · Northwestern University (2) · Novartis Pharmaceuticals (2)
China (52) · United States (30) · United Kingdom (12) · France (10) · Italy (10) · Canada (9) · Germany (9) · Spain (8) · Japan (7) · Czechia (6) · Denmark (6) · India (6) · Netherlands (6) · Belgium (5) · Sweden (5)
David Jayne, MD (2) · Dong-Xin Wang, MD, PhD (2) · Eric M Graham, MD (2) · Luo Zhang (2) · Peter A Merkel, MD, MPH (2) · Ritesh Agarwal, MD, DM (2) · Vir S Negi, DM (2) · Ana D Fernandes, MA (1) · Anja Pfaff, PhD (1) · Barry Simon, MD (1)
PMID 39425055, PMID 10068416, PMID 10517721, PMID 10683005, PMID 11334386, PMID 12727961, PMID 12826640, PMID 16221103, PMID 16622259, PMID 17332971, PMID 17923793, PMID 18000630, PMID 18421188, PMID 18535733, PMID 19138419, PMID 19337012, PMID 20054700, PMID 20478449, PMID 21510801, PMID 21802835, PMID 22252942, PMID 22619349, PMID 22925653, PMID 23227861, PMID 23587468, PMID 23870160, PMID 24203065, PMID 24694337, PMID 26585431, PMID 26952547, PMID 27013022, PMID 27117874, PMID 27924855, PMID 28246067, PMID 28388956, PMID 28945869, PMID 29195618, PMID 29247107, PMID 29331473, PMID 29961816, PMID 30561849, PMID 31132016, PMID 31206501, PMID 31260678, PMID 31668569, PMID 31671877, PMID 32053298, PMID 32162821, PMID 32374395, PMID 32392512
2016 (2), 2025 (2), R01HL115041 (2), 2009 (1), 2017 (1), 2018 (1), 2023 (1), R01HL112968 (1), R37HL068546 (1), U54AR057319 (1)